Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | MTOR | P42345 | 20/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.78 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.78 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.78 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.78 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.78 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.78 |
| ▸ | RPTOR | Q8N122 | 4/20 | 0.74 |
| ▸ | MLST8 | Q9BVC4 | 4/20 | 0.74 |
| ▸ | RICTOR | Q6R327 | 3/20 | 0.74 |
| ▸ | MAPKAP1 | Q9BPZ7 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29879892 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL29880159 | 0.95 | MTOR (0.90) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL19616562 | 0.95 | MTOR (0.90) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL1311809 | 0.89 | MTOR (0.80) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL1311369 | 0.89 | MTOR (0.80) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL29879988 | 0.88 | PIK3CA (1.00) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL1309466 | 0.88 | PIK3CA (1.00) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL23227108 | 0.87 | PIK3CA (0.76) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL20693026 | 0.85 | PIK3CA (0.76) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL21682466 | 0.85 | MTOR (1.00) | PIK3CAMTORPIK3R1PIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | claimed |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2024-11-21 | — | — | US | claimed |
| US-11918586-B2 | Treatment of skin lesions | TORQUR AG (CH) | 2024-03-05 | — | — | US | claimed |
| CN-109414415-B | Treatment of skin lesions | 拓客股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-11414426-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2022-08-16 | — | — | US | claimed |
| US-20210361665-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2021-11-25 | — | — | US | claimed |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2019-09-26 | — | — | US | claimed |
| US-20260062419-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | disclosed |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-11918586-B2 | Treatment of skin lesions | TORQUR AG (CH) | 2024-03-05 | — | — | US | disclosed |
| CN-109414415-B | Treatment of skin lesions | 拓客股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2023-01-19 | — | — | US | disclosed |
| CN-111315384-A | Treatment of skin disorders | 皮奎尔治疗公司 | 2020-06-19 | — | — | CN | disclosed |
| US-10640516-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIQUR THERAPEUTICS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2019-09-26 | — | — | US | disclosed |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2019-09-26 | — | — | US | disclosed |
| US-20190284178-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2019-09-19 | — | — | US | disclosed |
| WO-2019101853-A1 | TREATMENT OF SKIN DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2019-05-31 | — | — | WO | disclosed |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361665-A1 | TREATMENT OF SKIN LESIONS | CXCR3, C3AR1, CCR3 | PIK3CA 3770/4885MTOR 4061/4885PIK3R1 3165/4885 |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | C1R, C3AR1, CXCR3 | PIK3CA 3499/4885MTOR 4135/4885PIK3R1 2951/4885 |
| US-20260062419-A1 | TREATMENT OF SKIN DISORDERS | POLR1C, CCR1, COL1A1 | PIK3CA 3453/4885MTOR 3397/4885PIK3R1 3285/4885 |
| US-12497407-B2 | Treatment of skin disorders | RXFP3, CCR3, CBR3 | PIK3CA 4158/4885MTOR 3212/4885PIK3R1 2100/4885 |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CCR3, CBR3 | PIK3CA 4158/4885MTOR 3212/4885PIK3R1 2100/4885 |
| US-10640516-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | PIK3CA 1/4885MTOR 2/4885PIK3R1 30/4885 |
| US-11918586-B2 | Treatment of skin lesions | C1R, C3AR1, CXCR3 | PIK3CA 3499/4885MTOR 4135/4885PIK3R1 2951/4885 |
| US-11414426-B2 | Treatment of skin disorders | RXFP3, CBR3, CXCR3 | PIK3CA 3974/4885MTOR 2897/4885PIK3R1 1902/4885 |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | PIK3CA 1/4885MTOR 2/4885PIK3R1 30/4885 |
| US-20190284178-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM1, CHRM2, C1R | PIK3CA 4513/4885MTOR 4473/4885PIK3R1 3948/4885 |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | CXCR3, CCR3, C3AR1 | PIK3CA 3971/4885MTOR 4107/4885PIK3R1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.